As a world-leading gene therapy company, we are continuously advancing AAV therapeutics, discovering new technology, forging new research collaborations, and adding amazing talent to our team.
AskBio today announced that Sheila Mikhail, AskBio’s Chief Executive Officer and Co-founder, has been invited to provide an overview of the company at the 38th…
– AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease –
Recognition highlights $235 million investment fueling growth of company and its industry-leading gene therapy technology platform
Scientific leaders in cell and gene therapy collaborate to determine efficacy of SQZ tolerizing antigen carriers (TACs) containing AAV components to overcome patient immune responses…
National award recognizes outstanding entrepreneurial women who lead high-growth companies that are transforming their industries
Editas and AskBio, today announced the companies have entered a strategic research collaboration to explore in vivo delivery of genome editing medicines to treat neurological…
Expands AAV gene therapy platform from inside the cell for genetic disorders
Certification confirms Viralgen’s commitment to high operational standards with the world’s most flexible and robust AAV manufacturing capability
New $500 million gene therapy manufacturing facility in North Carolina further validates AskBio’s groundbreaking AAV gene therapy accomplishments
Synpromics to operate as a wholly owned subsidiary; the two companies bring together pioneering technology to increase efficacy of gene therapeutics
Development pipeline and human trials planned for repeat dosing of AAV-based gene therapies to address the unmet medical need for patients with rare and orphan…
Pfizer reported results from a Phase 1b clinical trial of PF-06939926, its investigational gene therapy for Duchenne Muscular Dystrophy (DMD).
AskBio continues to lead the path for gene therapy development and cost-effective manufacturing methods based on the contributions of its co-founder, Dr. Jude Samulski
Leading gene therapy company announces $235 million investment to accelerate growth
-Initial clinical study to evaluate ACTUS-101 over 52 weeks that could improve quality of life for those who are affected with rare genetic disorder -…
Asklepios BioPharmaceutical,Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
Company will target rare genetic diseases including Pompe Disease
New vector core facility will be located in San Sebastián, Spain
Up to 25 percent improvement in large animal model
Acquisition combines Bamboo’s gene therapy portfolio, advanced vector design, and production technologies and capabilities with Pfizer’s global scale, research, development and commercialization experience
Baxter has agreed to acquire all of Chatham’s outstanding membership interests.
AskBio announced today it has entered into a patent license agreement with Pfizer, Inc.
NanoCor Therapeutics, Inc. (NanoCor) today announces an investment by Medtronic, Inc. of $3.75 million.
Triangle-based AskBio to pay up to $240M for rights to use gene therapy technology December 19, 2019
2020: New Decade, New Disruption : Cell and Gene Therapy to Eradicate Genetic Diseases December 3, 2019
SQZ Biotech and AskBio Collaborate to Overcome AAV Immunogenicity December 3, 2019
R. Jude Samulski: Gene Therapy’s Guiding Force November 9, 2019
Executive Profile: A Voyage Above and Beyond November 2019
Cover Story: AskBio’s tumultuous ride to achieve unicorn status July 09, 2019
Top 10 gene therapy companies in 2019 June 06, 2019
Meet Sheila Mikhail, Co-Founder of AskBio May 28, 2019
How this promising gene therapy for a rare neuromuscular disease was fueled by passionate parents and a dog May 7, 2019
AskBio Gets $235 Million in Gene Therapy Support April 12, 2019
AskBio Banks $235 Million Investment To Accelerate Growth April 11, 2019
TPG, VIDA back AskBio in $235 Million Round April 11, 2019
AskBio’s $235 Million Financing Provides Clues to the Direction of Gene Therapy Investment April 11, 2019
M&A Wrap April 11, 2019
AskBio reels in $235M to ramp up gene therapy clinical trials, manufacturing April 11, 2019
Jude Samulski Named to North Carolina Power 100 January 29, 2019
Check out the conferences and events we are attending and where we are speaking.
Next-Generation Gene and Cell Technologies will be on January, 13, 2020 from 9:05am – 9:50am PST
AskBio CEO Sheila Mikhail was recognized at Springboard Enterprises’ 13th Annual Winners’ Circle Dinner, as the 2019 Northstar honoree.
AskBio CEO Sheila Mikhail presented at the 3rd annual Chardan Genetic Medicines Conference in New York.
Sheila Mikhail, CEO, of AskBio presented our differentiating capabilities, technology and therapeutic pipeline.
Dee Commodore, Andy Holt, Candace Summerford, and Pamela Ghosh represented AskBio at the annual Harvard Career Fair presented by the GSAS Harvard Biotech Club.
Joy Carson and Sharon Hesterlee, joined patients, families and leading stakeholders at the first-annual National Limb Girdle Muscular Dystrophy Conference in support of the LGMD…
AskBio’s Jude Samulski and Sharon Hesterlee joined the 25th Parent Project Muscular Dystrophy in Orlando.
AskBio’s Chief Medical Officer Martin K. (Casey) Childers, DO, PhD at the 22nd Annual Conference of the American Society of Gene & Cell Therapy.
Gene Therapy Panel (Alliance for Regenerative Medicine)
The Growing Promise of Gene Therapy Approaches
We take pride in our relationships with media representatives. Our scientific experts are always available if needed for interviews and their insights.
Robin Fastenau, Vice President, Communications